iiinova — where your digital self keeps evolving

Kyrie Pappas, PhD

@kyriepappas.bsky.social

26 followers 51 following 2 posts

Senior Research Scientist at Memorial Sloan Kettering Cancer Center Cancer Biologist | Translational Research | Drug Discovery | Targeted Therapy | Biomarker Research

Posts Replies Media

Reposted by Kyrie Pappas, PhD

The Charles Sawyers Lab @sawyerslabmskcc.bsky.social · 05/02/2026

OUT NOW: FOXA1 mutations co-opt nascent transcription factor networks in partnership with androgen receptor to enhance prostate tumorigenicity: Cell Reports www.cell.com/cell-reports... @mskcancercenter.bsky.social @cellpress.bsky.social @erikladewig.bsky.social #SawyersLabMSKCC

FOXA1 mutations co-opt nascent transcription factor networks in partnership with androgen receptor to enhance prostate tumorigenicity

Ladewig et al. show that distinct Foxa1 mutations reprogram chromatin, altering epithelial lineage specification. Indels promote basal-like states, whereas C-terminal truncations, Wing2 missense mutat...

Reposted by Kyrie Pappas, PhD

The Charles Sawyers Lab @sawyerslabmskcc.bsky.social · 08/09/2025

OUT NOW: ERG-driven prostate cancer initiation is cell-context dependent and requires KMT2A and DOT1L rdcu.be/eEVKR @mskcancercenter.bsky.social @natureportfolio.nature.com #SawyersLabMSKCC

ERG-driven prostate cancer initiation is cell-context dependent and requires KMT2A and DOT1L

Nature Genetics - Lineage tracing in mice identifies a subpopulation of basal cells that express Tmprss2 and Nkx3 as the origin of ERG-driven prostate cancer. Upon expansion, these cells show an...

Kyrie Pappas, PhD @kyriepappas.bsky.social · 12/06/2025

Excited to share our recent work published in PNAS last week uncovering the molecular mechanisms of PARP inhibitor resistance in BRCA2-deficient metastatic castration-resistant prostate cancer (mCRPC). Check out our manuscript!